{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:49:52Z","timestamp":1782305392830,"version":"3.54.5"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Atopic dermatitis (AD)-like graft-versus-host disease (GVHD) is a chronic form of skin GVHD with features that include erythema, xerosis, scaling, and pruritus. Patients often require treatment with systemic immunosuppression and aggressive topical therapies for relief. Long-term effects of chronic immunosuppression are undesirable and alternative therapies are needed. A retrospective review of 3 patients receiving dupilumab (DUP) for AD-like cGVHD was conducted. Data collected included demographics, transplant history, and GVHD management and outcomes. Information relating to DUP included dose, route, frequency, and safety based on dermatologic reactions, ocular toxicities, and infections. Patients had differing underlying conditions, transplant types, cell sources, and GVHD prophylactic therapies. Three patients received tacrolimus and topical corticosteroids for GVHD treatment, and 1 also received sirolimus and ruxolitinib. After the initial DUP dose, all patients experienced improvement in their GVHD. To date, all patients have complete remission of their skin cGVHD and have weaned off other therapies. No patients experienced dermatologic or ocular toxicities, and no infections were reported. DUP was efficacious and safe for treating AD-like cGVHD in our 3 pediatric patients. Further investigations are warranted to determine the appropriate placement in therapy.<\/jats:p>","DOI":"10.1097\/mph.0000000000003018","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T21:00:08Z","timestamp":1741986008000},"page":"e128-e130","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Dupilumab for Atopic Dermatitis-like Chronic Graft-versus-Host Disease in Three Pediatric Hematopoietic Cell Transplant Recipients"],"prefix":"10.1097","volume":"47","author":[{"given":"Savannah L.","family":"Ishee","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Monroe Carell Jr. Children\u2019s Hospital at Vanderbilt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith M.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Monroe Carell Jr. Children\u2019s Hospital at Vanderbilt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Connelly","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"R1-20250422","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"},{"key":"R2-20250422","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/cells13050425","article-title":"Unraveling atopic dermatitis: insights into pathophysiology, therapeutic advances, and future perspectives","volume":"13","author":"Pareek","year":"2024","journal-title":"Cells"},{"key":"R3-20250422","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2019.08.005","article-title":"Increased regulatory T cells and eosinophils characterize atopic dermatitis-like graft-versus-host disease compared with lichen planus-like graft-versus-host disease","volume":"83","author":"Li","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R4-20250422","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaad.2012.12.970","article-title":"Atopic dermatitis-like presentation of graft-versus-host disease: a novel form of chronic cutaneous graft-versus-host disease","volume":"69","author":"Wei","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"R5-20250422","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/pde.15146","article-title":"Atopic dermatitis-like graft-versus-host disease treated with dupilumab","volume":"40","author":"Larijani","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"R6-20250422","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jdcr.2023.11.003","article-title":"Successful use of dupilumab in recalcitrant pediatric atopic dermatitis-like graft-versus-host disease: a case series","volume":"44","author":"Belmesk","year":"2023","journal-title":"JAAD Case Rep"},{"key":"R7-20250422","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"R8-20250422","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaad.2020.11.042","article-title":"Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration","volume":"84","author":"Wang","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R9-20250422","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T14:00:54Z","timestamp":1745330454000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003018","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"2024-10-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}